GBIM:OTCMKTS
GlobeImmune Inc
US$ 0.00010
0.00%
(0.00) Siku 1
29 Sep, 15:48:52 GMT -4 · USD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya GBIM...
Mtaji wa soko
580.00
Wastani wa kiasi cha mauzo
elfu 1.74
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
US$ 0.04
Chini kwa wiki 52
US$ 0.00
Hisa za wawekezaji
5.75M
Idadi ya wafanyakazi
22
Mtaji wa soko
580.00
Wastani wa kiasi cha mauzo
elfu 1.74
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
US$ 0.04
Chini kwa wiki 52
US$ 0.00
Hisa za wawekezaji
5.75M
Idadi ya wafanyakazi
22
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
WXXV News 25
·
dakika 49 zilizopita
US markets are weighed down by an extended sell-off in the tech sector
MarketWatch
·
saa 6 zilizopita
Don’t buy this dip: Several signs suggest there’s more pain ahead for tech stocks
CNN
·
saa 8 zilizopita
Nasdaq sinks more than 2% as investors raise questions about AI debt
Yahoo Finance
·
saa 2 zilizopita
Dow (DOW) Stock Could Look Reasonable After a 43% Gain
Wasifu
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010.
As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia
Kuhusu GlobeImmune Inc
Afisa Mkuu Mtendaji (CEO)-
Wafanyakazi22
Lilianzishwa1 Jan 1995
Makao makuuLouisville, Colorado, Marekani
Sekta-
Tovutiglobeimmune.com